- Home
- PSF vs CRVS Comparison
PSF vs CRVS Comparison
Compare PSF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- CRVS
- Stock Information
- Founded
- PSF 2010
- CRVS 2014
- Country
- PSF United States
- CRVS United States
- Employees
- PSF N/A
- CRVS N/A
- Industry
- PSF Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- CRVS Health Care
- Exchange
- PSF Nasdaq
- CRVS Nasdaq
- Market Cap
- PSF 244.3M
- CRVS 206.5M
- IPO Year
- PSF N/A
- CRVS 2016
- Fundamental
- Price
- PSF $18.94
- CRVS $3.24
- Analyst Decision
- PSF
- CRVS Strong Buy
- Analyst Count
- PSF 0
- CRVS 3
- Target Price
- PSF N/A
- CRVS $15.67
- AVG Volume (30 Days)
- PSF 25.0K
- CRVS 884.2K
- Earning Date
- PSF 01-01-0001
- CRVS 05-05-2025
- Dividend Yield
- PSF 7.69%
- CRVS N/A
- EPS Growth
- PSF N/A
- CRVS N/A
- EPS
- PSF N/A
- CRVS N/A
- Revenue
- PSF N/A
- CRVS N/A
- Revenue This Year
- PSF N/A
- CRVS N/A
- Revenue Next Year
- PSF N/A
- CRVS N/A
- P/E Ratio
- PSF N/A
- CRVS N/A
- Revenue Growth
- PSF N/A
- CRVS N/A
- 52 Week Low
- PSF $16.00
- CRVS $1.30
- 52 Week High
- PSF $20.19
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PSF 42.48
- CRVS 42.22
- Support Level
- PSF $18.51
- CRVS $2.80
- Resistance Level
- PSF $18.94
- CRVS $3.37
- Average True Range (ATR)
- PSF 0.46
- CRVS 0.27
- MACD
- PSF -0.01
- CRVS 0.07
- Stochastic Oscillator
- PSF 44.89
- CRVS 78.65
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).